Zur Huntington-Erkrankung im Kindes- und Jugendalter – Erkrankung, klinische Präsentation und Probleme der Diagnostik

Zusammenfassung

Die Huntington-Erkrankung (HD) ist eine autosomal-dominante neurodegenerative Erkrankung, die vornehmlich zwischen dem 30. und 50. Lebensjahr auftritt. Verursacht wird sie durch eine Genmutation auf dem Chromosom 4, welche zu einer Tripletexpansion (CAG) führt. Weniger als 10% der Betroffenen erkranken vor dem 20. Lebensjahr. Die beim Erwachsenen typischen choreatiformen Bewegungsmuster tauchen beim Jugendlichen erst im späteren Verlauf auf, können aber auch ganz fehlen. Etwa ein Drittel der Jugendlichen entwickelt eine Epilepsie.

Wir präsentieren sechs Fälle kindlicher/juveniler HD und beschreiben vergleichend zur adulten HD Erstsymptome, genetische Befunde und weitere Besonderheiten.

Die klinische Präsentation und auch der Erkrankungsverlauf der jugendlichen HD-Patienten unterscheiden sich mitunter deutlich von der adulten Form. Es imponieren initial vor allem Teilleistungsstörungen bei den Kindern sowie psychiatrische Symptome wie Depression und Aufmerksamkeitsstörungen bei den Jugendlichen.

Aufgrund der niedrigen Prävalenz juveniler HD sowie der variablen klinischen Symptomatik ist eine Diagnosestellung im Kindes- und Jugendalter schwierig und gelingt oftmals erst mit einer zeitlichen Latenz. Die frühe Diagnosestellung kann allerdings wichtig sein, insbesondere, um soziale und schulische Probleme zu entschärfen.

Abstract

Huntington’s disease (HD) is an autosomal-dominant neurodegenerative disorder caused by a gene mutation in chromosome 4 that leads to an expansion of CAG - triplet repeats. It occurs mainly between the age of 30 and 50. Only less than 10 % of HD patients are younger than 20 years. In contrast to adult patients young HD patients show more often psychiatric and cognitive symptoms at disease onset than chorea. One third of the children with HD develops an epilepsy.

We present 6 children diagnosed with HD in different stages of childhood. We describe first symptoms as well as genetic characteristics and other distinctive features.

Both, the clinical presentation and the course of HD in childhood differ from HD in adults. In adolescents the clinical symptoms at onset are often psychiatric (like depression or attention deficit disorder). Choreatic movements typical for adult HD patients are missing.

Due to the low prevalence of HD in childhood and the variability of clinical symptoms the process of diagnosing HD in children is difficult. Very often the diagnosis is made years after the first symptoms. Early diagnosis, however, is often important for managing social problems and problems in school.

Schlüsselwörter

Huntington-Erkrankung - Kindheit - Neurodegeneration - Tripleterkrankung - Epilepsie

Key words

Huntington’s disease - Childhood - Neurodegeneration - Triplet disease - Epilepsy

Publication History

Received: 14 June 2019

Accepted: 12 December 2019

Article published online:
05 May 2020

• Literatur

• 1 Vonsattel JPG, Keller C, Ramirez EPC. Huntington’s disease – Neuropathology. Feigin A, Anderson K. eds. Handbook of Clinical Neurology. 144. Science Direct; 2011: 15-28;
• 2 Saft C. What is the course of Huntington’s disease?. Lancet Neurol 2014; 13: 1165-6016
• 3 Schwarz M. Chorea. Berlit P. Hrsg. Klinische Neurologie. Berlin Heidelberg New York: Springer-Verlag; 2011: 1019-1025
• 4 Nance MA. US Huntington Disease Genetic Testing Group. Genetic testing of children at risk for Huntington’s disease. Neurology 1997; 49: 1048-1053
• 5 Rasmussen A, Macias R, Yescass P. et al. Huntington Disease in children: Genotype- phenotype correlation. Neuropediatrics 2000; 31: 190-194
• 6 The Huntington’s Disease Research Collaborative Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 1993; 72: 971-983
• 7 Semaka A, Creighton S, Warby S. et al. Predictive testing for Huntington disease: Interpretation and significance of intermediate alleles. Clin Genet 2006; 70: 283-294
• 8 Saft C, Leavitt BR, Epplen JT. Clinical utility gene card for: Huntington’s disease. Eur J Hum Genet 2014; 22.
• 9 Süssmuth SD, Saft C, Reilmann R. et al. Neues zur Huntingtonkrankheit. Akt Neurol 2013; 40: 377-392
• 10 Yoon G, Kramer J, Zanko A. et al. Speech and language delay are early manifestations of juvenile-onset Huntington disease. Neurology 2006; 67: 1265-1267
• 11 Ribaï P, Nguyen K, Hahn-Barma V. et al. Psychiatric and cognitive difficulties as indicators of juvenile huntington disease onset in 29 patients. Arch Neurol 2007; 64: 813-819
• 12 Ben-Pazi H, Jaworowski S, Shalev RS. Cognitive and psychiatric phenotypes of movement disorders in children: A systematic review. Dev Med Child Neurol 2011; 53: 1077-1084
• 13 Lambeck J, Niesen WD, Matthias R. et al. Substantia nigra hyperechogenicity in hypokinetic Huntington’s disease patients. J Neurol 2015; 262: 711-717
• 14 Saft C, Hoffmann R, Strassburger-Krogias K. et al. Echogenicity of basal ganglia structures in different Huntington`s disease phenotype. J Neural Transm (Vienna) 2015; Jun; 122 (06) 825-833
• 15 Ellrichmann G, Reick C, Saft C. et al. The rolle of the immune system in Huntington`s disease. Clin Dev Immunol 2013; 2013: 541259
• 16 Saft C, Zange J, Andrich J. et al. Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington’s disease. Mov Disord 2005; 20: 674-679
• 17 Stüwe SH, Goetze O, Lukas C. et al. Hepatic mitochondrial dysfunction in manifest and premanifest Huntington disease. Neurology 2013; 80: 743-746
• 18 Saft C. et al. S2k-Leitlinie Chorea/Morbus Huntington. Deutsche Gesellschaft für Neurologie. Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie,. 2017. Online www.dgn.org/leitlinien
• 19 Borek LL, Friedman JH. Treating psychosis in movement disorder patients: A review. Expert Opin Pharmacother 2014; August; 15 (11) 1553-1564
• 20 Thiels C, Saft C, Stahl A. et al. Denial mechanisms cause delay of diagnosis in families with hereditary Huntington`s disease. Poster EPNS, 2013
• 21 Nance MA, Myers RH. Juvenile onset Huntington’s disease – clinical and research perspectives. Mental Retard Dev Disabil Res Rev 2001; 7 (03) : 153-157
• 22 Quaid KA. Genetic testing for Huntington disease. Handb Clin Neurol 2017; 144: 113-126
• 23 Andrew SE, Goldberg YP, Kremer B. et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington’s disease. Nat Genet 1993; 4: 398-403
• 24 Snell RG, MacMillan JC, Cheadle JP. et al. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington’s disease. Nat Genet 1993; 4: 393-397
• 25 Comunale Jr JP, Heier LA, Chutorian AM. Juvenile form of Huntington’s disease: MR imaging appearance. AJR Am J Roentgenol 1995; August; 165 (02) 414-415
• 26 Ho VB, Chuang HS, Roira MJ. et al. Juvenile Huntington Disease: CT and MR features. Am J Neuroradiol 1995; 16: 1405-1412
• 27 Vonsattel JP, Cortes EP, Keller CE. Huntington’s disease – neuropathology. Handb Clin Neurol 2011; 100: 83-100
• 28 Rüb U, Hoche F, Brunt ER. et al. Degeneration of the Cerebellum in Huntington’s Disease (HD): Possible Relevance for the Clinical Picture and Potential Gateway to Pathological Mechanisms of the disease Process. Brain Pathol 2013; Mar; 23 (02) 165-177
• 29 Saft C, von Hein SM, Lücke T. et al. Cannabinoids for Treatment Dystonia in Huntington’s Disease. J Huntington Dis 2018; 7 (02) : 167-173
• 30 Cloud LJ, Rosenblatt A, Margolis RL. et al. Seizures in juvenile Huntington’s disease: Frequency and characterization in a multicenter cohort. Mov Disord 2012; 27: 1797-1800
• 31 Saft C, Lauter T, Kraus PH. et al. Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington’s Disease patients: A case series. BMC Neurol 2006; 6: 11